Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of BPB-101 in advanced malignant solid tumors
CTR20230858Phase 2Active
- Sponsor
- Betta Pharmaceuticals
- Start
- May 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BPB-101 in Nonhematologic neoplasms, sponsored by Betta Pharmaceuticals. Started May 2023; status: active.
02
Drugs
BPB-101
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20230858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230858.